SYNOPSIS

8th BOSTON PARIS BIOTECHNOLOGY SUMMIT™

An exclusive, Trans-Atlantic bridge designed to foster innovative synergies between biotech and pharma companies, healthcare-focused cities, regional clusters and institutional, philanthropic and strategic investors. 

The Summit’s intent is to spark projects, their financing and strategic deals to solve unmet medical needs to improve patient lives globally.

The 8th Boston Paris Biotechnology Summit™ 2024 has three components:

(1)      IN-PERSON I: 15 May 2024 at CIC CAMBRIDGE 02142 MA, USA

(2)      LIVE STREAM 15 May 2024 from at CIC CAMBRIDGE 02142 MA, USA,

          Via a ZOOM PLATFORM.

(3)      IN-PERSON II: Business France PANEL DISCUSSION, on 5 June 2025 at the        Pavilion de France, International BIO Convention, Exhibition Area,

          San Diego 92101 CA.

2024 CORE THEME:

BUILDING MECANISMS FOR CUSTOMIZED SUCCESS PLANS.

—————————————————————————————————————-

SUMMIT SESSIONS:

  • PERSPECTIVES ON NEW DRUG DISCOVERY FROM A PATIENT-SCIENTIST.
  • INTERNATIONAL START UP PITCH COMPETITION.
  • US ECONOMY & CASH FLOW FOR INVESTMENTS.
  • LATEST DATA AND PERSPECTIVES FOR BIOTECHNOLOGY EXECUTIVES.
  • [MASTER CLASS]: Optimal Roadmap from a New Idea to a Helpful Medicine?
  • Perspectives from a Pharmaceutical Executive & Academic Leader.
  • NOVEL ROADMAPS FOR THE DELIVERY OF NEW MEDICINES TO PATIENTS.
  • APPLICATIONS OF AI & MACHINE LEARNING TO BIOTECHNOLOGY R&D: Academic and Industrial Perspectives.

The co-founders would like to acknowledge the key contributions of Sponsors to this 8th Edition:

  • PPD BIOTECH [Thermo Fisher Scientific Group], USA [Founding Sponsor]
  • CPL Life Sciences, London UK [Founding Sponsor]
  • MCDERMOTT, WILL & EMERY, Boston USA [Founding Sponsor]
  • BANOOK Group, France
  • JAB Law Firm, Boston, USA
  • TRIRADIAL SOLUTIONS, New Jersey, USA
  • HORIANA, San Francisco, CA, USA
  • FRENCH TECH BOSTON.

SPEAKERS & SESSION MODERATORS (in alphabetical order):

  • Azim DEHGHANI AMIRABAD, Senior AI-Machine Learning Scientist | Generative AI, Johnson & Johnson Group, Boston MA.
  • Kevin J. BITTORF, PhD, MBA, PEng @ SCxCMC and Forum for Advances in Drug Development, Boston MA.
  • Vanessa EL HARRAR, Vice President, Global Medical Officer, Vaccines and Government Services, PPD, part of Thermo Fisher Scientific.
  • Geoff GARABEDIAN, CEO, TRIRADIAL SOLUTIONS, New Jersey, USA.
  • Trang GISSLER Senior Director, Government and Public Health Services, Clinical Research Group. Formerly FDA Management and Operations in the Office of the Commissioner. R.
  • Thomas HANCOX, Vice-President, CPL Life Sciences, Boston MA & London, UK.
  • Sru JAMINDAR, MBA. Executive Director, Venture Engagement, Thermo Fisher Group, Boston MA.
  • Matthias LAMBERT, 2024 recipient of the Harvard Medical School Faculty Award and a PhD scientist working on muscle biology, muscular dystrophy, myopathy.

Furthermore, Dr. Lambert is also a patient, living with a rare muscle disease.

  • Charles “Chuck” LARSON, McDermott Will & Emery International Law Firm, US Attorney & UK Solicitor. Best Lawyers in the US_2024 Edition.
  • Mark NAMCHUK, Professor and Executive Director, Translational Medicine, Harvard Medical School, Boston MA. CEO, DECOY Therapeutics, Cambridge MA, Serial Entrepreneur, Boston MA.
  • Frederick “Rick” PIERCE II, CEO DECOY Therapeutics. Cambridge MA, Serial Entrepreneur, Boston MA.
  • Mark DE ROSCH, FRAPS: Fellow, Regulatory Affairs Society, Boston MA.
  • Samuel SCARPINO, Director of AI + Life Sciences, Institute for Experiential AI.

Professor of the Practice, Bouvé College of Health Sciences & Khoury College of Computer Sciences @ Northeastern University, Boston MA.

  • John TRAYNOR, President, Cambridge Trust Wealth Management of Connecticut, Southport, Conn.
  • Jerome WINDSOR, Senior Vice President, BD & Strategic Alliances, AITIA BIO, Boston MA.

SUMMARIES OF SELECTED PRESENTATIONS

(in order of presentation)

  • PERSPECTIVES ON NEW DRUG DISCOVERY FROM A PATIENT-SCIENTIST.
  • We are currently witnessing a scientific and medical revolution;
  • Do not just witness it, be part of it!
  • Listen to the patients;
  • Include and support patients in decision-making processes;
  • There are 9000+ rare diseases – we cannot study them all at once;
  • We need to turn hope into action;
  • A new business model is required: turning companies into service providers first, and product providers second;
  • We need of new culture of cooperation.
  • INTERNATIONAL PITCH COMPETITION SESSION:

JURY:

  • Leslie COUSENS, PhD, Boston MA, USA [JURY CHAIR]

GI Search & Evaluation Lead, R&D Business Development Center for External Innovation,

TAKEDA PHARMACEUTICALS.●

  • Jennifer A. BOCK, JD, Boston MA, USA

Managing Partner JAB Law.●

  • Eric EVANS, Master in Finance, Boston MA, USA

Executive Committee, MA2: Mass Medical Angels, a seed stage investor focused exclusive on life science and healthcare investments.●

  • Jessica FOLEY, MS, RAC, Boston MA, USA

RAC: Regulatory Affairs Certified

GAIA Consulting LLC @ CIC Cambridge MA. Senior Regulatory Consultant●

  • Naji GEHCHAN, MD, Boston MA, USA

Global Development Leader Oncology, ELI LILLY & CO.●

  • Kristin KING, MBA, Greater NY METRO Area, USA

Representing Boston Harbor Angels. Vice President – Corporate Development, M&A. Defibtech LLC.●

  • Albert MOUSSA, DEng, Boston MA, USA

Executive Angel Investor. Representing Launchpad Ventures, LLC.●

  • US ECONOMY & CASH FLOW FOR INVESTMENTS:
  • General cooling of inflation
    • We saw peak inflation in June 2022 when the CPI rose to 9.1%. The March 2024 report on the CPI showed a reacceleration in the first quarter, but expectations are for inflation to slowly cool.  The PCE rose by 2.8% in March, but the quarterly annual rate was a disconcerting 3.7%. 
    • The economy is slowly cooling
    • The US economy reaccelerated in late 2023 as consumer spending and business investment in inventories remained strong.  First quarter GDP rose by 1.6% while real final demand rose by 3.1%.
    • In early 2023, the Conference Board estimated US GDP would grow 0.0% in 2023, but it actually grew by 2.5%. Our current estimate is 2.5% in 2024 and 2.0% in 2025.
    • Employment is slowly cooling
    • The April unemployment rate was 3.9%, up from 3.8% in the previous month.
    • Jobs grew by 175,000, below the estimate of 240,000.
  • [MASTER CLASS]:

Optimal Roadmap from a New Idea to a Helpful Medicine?

  • Academia and industry should be partnering to attain unfeasible objectives.
  • Industry does not need academia to drive incremental improvement.
  • Ultimately you have no control of if your idea is right, only how quickly you can find out.
  • Most of our processes in moving from an idea to medicine focus more on financial and business risk rather on than achieving rapid scientific progress.
  • Our singular focus should be to optimize the speed at which a new idea can become a helpful medicine.
  • ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
  1. AI is going to change the way we work, but exactly how is up to us. That is why collaboration is so important.
  2. Data are the biggest factor in determining whether AI is likely to be useful. Investing in digital transformation is the best path to benefiting from AI.
  3. The field is moving rapidly, but there is still SO much we don’t understand. This includes what we mean by “intelligence”.

NOTA BENE:
We sincerely apologize to the speakers for not being able to reproduce their presentations in extenso.

****************************************************************************************************

PANEL DISCUSSION @ INTERNATIONAL BIO CONVENTION,

IN COLLABORATION WITH BUSINESS FRANCE:

5 JUNE 2024_Pavillon de France, San Diego Convention Center Exhibit Area.

Panel Expert Speakers (in alphabetical order):

  • Shahin Gharakhanian, Co-Founder & CEO Shahin Gharakhanian MD Consulting LLC, Program Chair, Boston Biotechnology Summit™ [Moderator].
  • Vanessa Elharrar, Vice President, Global Medical Officer, PPD

[Thermo Fisher Scientific Group].

  • Thomas HANCOX, Vice-President, CPL Life Sciences.
  • François RAVENELLE, CEO INVERSAGO, A Novo Nodisk Company.
  • James “Jamie” RAVITZ, Partner, McDermott Will Emery.

****************************************************************************************************

Soheila Gharakhanian, BS, Co-Founder, Principal, & Chair, Organizing Team Conference Producer: Blend of Concept LLC Cambridge MA 02140, USA BOSTON/PARIS BIOTECHNOLOGY SUMMIT™ SUMMIT 2024 www.bostonbiotechnologysummit.com   Shahin Gharakhanian, MD, DPH Co-Founder, Principal, & Program Chair Shahin Gharakhanian MD Consulting LLC CIC: Cambridge Innovation Center Cambridge MA 02142, USA.